We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current GLUE market cap is 425.76M. The company's latest EPS is USD -2.2031 and P/E is -3.14.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 1.06M | 4.7M | 9.22M |
| Operating Income | -36.97M | -34.86M | -34.95M | -32.64M | -26.53M |
| Net Income | -34.88M | -33.25M | -31.97M | -30.31M | -23.86M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.99M | -28.01M | -72.88M | -112.38M | -143.31M |
| Net Income | -7.74M | -35.88M | -73.96M | -108.5M | -135.35M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 252.1M | 303.76M | 266.75M | 344.11M | 315.08M |
| Total Liabilities | 67.58M | 124.51M | 114.23M | 119.44M | 109.62M |
| Total Equity | 184.52M | 179.25M | 152.52M | 224.67M | 205.46M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 11.09M | 49.38M | 366.33M | 342.39M | 303.76M |
| Total Liabilities | 4.29M | 30.34M | 18.81M | 70.98M | 124.51M |
| Total Equity | -12.15M | -48.73M | 347.52M | 271.41M | 179.25M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -73.44M | -43.8M | -38.17M | -65.93M | -86.93M |
| Investing | 74.5M | 88.8M | 9.85M | -51.31M | -13.56M |
| Financing | 2.32M | 27.49M | 246k | 98.27M | 98.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.17M | -23.05M | -59.36M | -92.47M | -43.8M |
| Investing | -1.39M | -3.39M | -9.65M | -219.22M | 88.8M |
| Financing | 15M | 60.06M | 377.56M | 20.47M | 27.49M |
| Market Cap | 425.76M |
| Price to Earnings Ratio | -3.14 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.31 |
| Price to Book Ratio | 2.37 |
| Dividend Yield | - |
| Shares Outstanding | 61.44M |
| Average Volume (1 week) | 1.84M |
| Average Volume (1 Month) | 1.76M |
| 52 Week Change | 24.64% |
| 52 Week High | 12.40 |
| 52 Week Low | 3.21 |
| Spread (Intraday) | 0.98 (13.01%) |
| Company Name | Monte Rosa Therapeutics Inc |
| Address |
corporation trust center 1209 orange st wilmington, delaware 19801 |
| Website | https://www.monterosatx.com. |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
